Walter Sunny Dzik

Massachusetts General Hospital, Boston, Massachusetts, United States

Are you Walter Sunny Dzik?

Claim your profile

Publications (8)28.48 Total impact

  • Transfusion 11/2014; 54(11). · 3.57 Impact Factor
  • Walter Sunny Dzik, Meghan Delaney
    Transfusion 11/2014; 54(11):2791-4. · 3.57 Impact Factor
  • Jeremy Ryan Andrew Peña, Walter Sunny Dzik
    [Show abstract] [Hide abstract]
    ABSTRACT: The scope of activity of the Blood Transfusion Service (BTS) makes it unique among the clinical laboratories. The combination of therapeutic and diagnostic roles necessitates a multi-faceted approach to utilization management in the BTS. We present our experience in utilization management in large academic medical center.
    Clinica chimica acta; international journal of clinical chemistry 09/2013; · 2.54 Impact Factor
  • Transfusion 06/2013; 53(6):1168. · 3.57 Impact Factor
  • Walter Sunny Dzik
    Transfusion medicine reviews 07/2012; · 4.54 Impact Factor
  • Walter Sunny Dzik
    [Show abstract] [Hide abstract]
    ABSTRACT: Anticoagulant drugs are taken by millions of patients throughout the world. Warfarin has been the most widely prescribed anticoagulant for decades. In recent years, new oral anticoagulants have been approved for use, are being positioned as alternatives to warfarin, and represent an enormous market opportunity for pharmaceutical companies. Requests for urgent reversal of anticoagulants are not uncommon especially in the setting of critical bleeding. This review summarizes information on reversal of warfarin by vitamin K, plasma, prothrombin complex concentrates, and recombinant VIIa. In addition, we emphasize the lack of current evidence supporting reversibility of the new oral direct thrombin inhibitors and Factor Xa inhibitors. This review is presented to assist transfusion medicine specialists, hematologists, and other clinicians who prescribe blood components for reversal of drug-induced anticoagulation.
    Transfusion 05/2012; 52 Suppl 1:45S-55S. · 3.57 Impact Factor
  • James P Aubuchon, Walter Sunny Dzik
    Transfusion 11/2009; 50(5):963-7. · 3.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Errors in the collection and labeling of blood samples for pretransfusion testing increase the risk of transfusion-associated patient morbidity and mortality. Statistical process control (SPC) is a recognized method to monitor the performance of a critical process. An easy-to-use SPC method was tested to determine its feasibility as a tool for monitoring quality in transfusion medicine. SPC control charts were adapted to a spreadsheet presentation. Data tabulating the frequency of mislabeled and miscollected blood samples from 10 hospitals in five countries from 2004 to 2006 were used to demonstrate the method. Control charts were produced to monitor process stability. The participating hospitals found the SPC spreadsheet very suitable to monitor the performance of the sample labeling and collection and applied SPC charts to suit their specific needs. One hospital monitored subcategories of sample error in detail. A large hospital monitored the number of wrong-blood-in-tube (WBIT) events. Four smaller-sized facilities, each following the same policy for sample collection, combined their data on WBIT samples into a single control chart. One hospital used the control chart to monitor the effect of an educational intervention. A simple SPC method is described that can monitor the process of sample collection and labeling in any hospital. SPC could be applied to other critical steps in the transfusion processes as a tool for biovigilance and could be used to develop regional or national performance standards for pretransfusion sample collection. A link is provided to download the spreadsheet for free.
    Transfusion 08/2008; 48(10):2143-51. · 3.57 Impact Factor